WEDNESDAY, Sept. 1 (HealthDay News) -- More isn't necessarily
better when prescribing the two drugs commonly used to treat
patients who are in danger of having a heart attack, Plavix
(clopidogrel) and aspirin, a new study suggests.
Two reports on the data find that high doses of Plavix are good
for some patients, but not all, while high-dose aspirin is no
better than a low dose for preventing new heart attacks, other
cardiac problems, stroke and death.
The findings suggest a need to assess the risks and benefits
individually, experts say.
Patients who are at high risk for heart attack and stroke and
low risk for bleeding are going to do well on a higher dose of
Plavix, said Dr. Gregg Stone, author of an editorial in
"Patients who are at lower risk for atherosclerotic complications, but high risk for bleeding should be treated with a more conservative lower dose," added Stone, director of cardiovascular research and education at Columbia University Medical Center in New York City.
The reports are being released Wednesday to coincide with the
meeting of the European Society of Cardiology in Stockholm. They
are also published in the Sept. 1 online edition of
The Lancet and in the Sept. 2 issue of the
New England Journal of Medicine.
While aspirin and Plavix are mainstays of treatment for those at
risk of having a heart attack, questions remain about proper
dosing. Too little medicine won't prevent clotting, which can lead
to heart attack, while too much can cause fatal bleeding.
To assess the best treatment regimens, the researchers assigned
25,086 patients at risk of having a heart attack (due to acute
coronary syndrome) to a standard dose or double dose of Plavix and
to high- or low-dose aspirin. Patients on the standard dose of
Plavix got 300 milligrams (mg) the first day followed by 75 mg
daily, while those with the double dose took 600 mg on day one,
followed by 150 mg for six days and 75 mg thereafter. Patient
outcome was evaluated after 30 days.
About two-thirds of the patients underwent percutaneous coronary
intervention (PCI), also known as angioplasty. This involved
threading a catheter with a balloon at the end through a blocked or
narrowed coronary artery and placing a small mesh tube, called a
stent, in the artery to keep it open.
After angioplasty, patients typically receive both Plavix and
aspirin to reduce the likelihood of clotting and re-blocking the
artery or the stent.
The researchers found that patients undergoing angioplasty
benefited from a double dose of Plavix, with their risk of heart
attack, stroke or death reduced 14 percent, compared with patients
who were given a standard dose. Moreover, the risk of clotting in
the stent was cut 46 percent among those receiving the double
However, the double-dose patients had a 41 percent increased
risk of bleeding compared to those getting the standard dose. This
led the researchers to recommend a standard dose for patients not
As for aspirin, no difference in adverse events was seen among
patients taking a high (300 or 325 mg) or low (75 to 100 mg) dose.
The researchers concluded that low-dose aspirin is best, since it
reduces the risk of bleeding without increasing the risk of
"Taken together, the message is very simple: We recommend that patients undergoing PCI receive the full double-dose regimen of clopidogrel, and those who do not have PCI should be treated with the standard-dose regimen of clopidogrel," said Dr. Shamir Mehta, an associate professor of cardiology at McMaster University in Ontario, Canada, and co-author of both reports.
Commenting on the study, another expert, Dr. Gregg C. Fonarow, a
professor of cardiology at the University of California, Los
Angeles, said he was surprised to find that the double dose wasn't
beneficial overall and that it increased the risk of bleeding.
"A double dose of clopidogrel is an attractive option for patients with acute coronary syndrome undergoing coronary interventions compared with standard dosing," Fonarow said. "However, alternative antiplatelet agents, such as prasugrel (Effient) or ticagrelor (Brilinta), also have been proven to offer incremental benefits to standard dosing with clopidogrel."
The trial was funded by the pharmaceutical giants Sanofi-Aventis
and Bristol-Myers Squibb, which make Plavix.
For more information on heart disease, visit the
American Heart Association.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.